Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 6,103 | 1,531 | 4,549 |
| Samples | 1,733 | 890 | 833 |
| Peptides | 930 | 248 | 707 |
Function
MUC3A · Mucin 3A, cell surface associated
The mucin genes encode epithelial glycoproteins, some of which are secreted and some membrane bound. Each of the genes contains at least one large domain of tandemly repeated sequence that encodes the peptide sequence rich in serine and/or threonine residues, which carries most of the O-linked glycosylation (Gendler and Spicer, 1995 [PubMed 7778880]).[supplied by OMIM, Aug 2008].
Isoforms & Proteins
2 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
Gene Properties
Recurrent Mutations
All 919 amino-acid changes on canonical ENST00000379458 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in MUC3A · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in MUC3A – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Cell Non-Hodgkins Lymphoma | 12/26 46% | 0/0 0% |
| Chronic Myelogenous Leukemia | 9/25 36% | 0/0 0% |
| T-Lymphoblastic Leukemia | 11/40 28% | 0/0 0% |
| Oral Cavity Carcinoma | 14/54 26% | 0/0 0% |
| Acute Myeloid Leukemia | 23/90 26% | 0/0 0% |
| Glioblastoma | 22/98 22% | 0/0 0% |
| Mesothelioma | 20/62 32% | 1/165 1% |
| Unknown | 3/10 30% | 0/29 0% |
| Melanoma | 62/210 30% | 96/1899 5% |
| Rhabdomyosarcoma | 14/33 42% | 0/171 0% |
| Other Solid Cancers | 46/94 49% | 61/1515 4% |
| Thyroid Gland Carcinoma | 16/45 36% | 91/1592 6% |
| Ewings Sarcoma | 21/63 33% | 0/262 0% |
| Neuroendocrine Tumour | 38/154 25% | 5/577 1% |
| Squamous Cell Lung Carcinoma | 13/57 23% | 37/810 5% |
| Osteosarcoma | 10/45 22% | 2/166 1% |
| Endometrial Carcinoma | 17/42 40% | 19/612 3% |
| Non-Small Cell Lung Carcinoma | 60/304 20% | 33/1390 2% |
| Colorectal Carcinoma | 46/143 32% | 108/3239 3% |
| Gastrointestinal Stromal Tumour | 0/0 0% | 6/133 5% |
| Ovarian Carcinoma | 37/109 34% | 11/998 1% |
| Plasma Cell Myeloma | 13/44 30% | 2/305 1% |
| Burkitts Lymphoma | 9/32 28% | 0/196 0% |
| Cervical Carcinoma | 14/35 40% | 4/422 1% |
| Bladder Carcinoma | 16/58 28% | 23/956 2% |
| Acute Monocytic Leukemia | 1/1 100% | 0/25 0% |
| Gastric Carcinoma | 24/74 32% | 45/1809 2% |
| Hodgkins Lymphoma | 5/16 31% | 0/122 0% |
| Germ Cell Tumour | 5/25 20% | 2/169 1% |
| Non-Cancerous | 27/104 26% | 5/830 1% |
Mutation Distribution
Where MUC3A is mutated · all tissues, split by cell line vs tissue
How many mutations in MUC3A were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 6,103 mutations in MUC3A
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|